TABLE 1.
Presenting characteristics of patients with ocular inflammation at the time of starting adalimumab.
| Characteristic | Patients |
|
|---|---|---|
| n | (%) | |
| Patients (n) | 32 | |
| Age (years) | ||
| Mean ± SD | 42 ± 21 | |
| Median (range) | 48 (4–74) | |
| Gender: male (%) | 10 | 31.3 |
| Race (%) | ||
| White | 25 | 78.1 |
| Black | 2 | 6.3 |
| Other | 3 | 9.4 |
| N/A | 2 | 6.3 |
| Diagnosis | ||
| Anterior uveitis | 15 | 46.9 |
| Intermediate uveitis | 3 | 9.4 |
| Posterior or panuveitis | 3 | 9.4 |
| Scleritis | 9 | 28.1 |
| Other | 2 | 6.3 |
| Duration of inflammation (years) | ||
| Mean ± SD | 6.9 ± 8.6 | |
| Median (range) | 3.0 (0–36) | |
| Prior therapy (%) | ||
| Topical corticosteroids | 23 | 71.9 |
| Oral corticosteroids | 14 | 43.8 |
| Corticosteroids via any route | 27 | 84.4 |
| IMT (%) | ||
| 1 IMT | 9 | 28.1 |
| 2 IMT | 13 | 40.6 |
| ≥3 IMT | 6 | 18.8 |
| Total | 28 | 87.5 |
| Active inflammation at treatment initiation (%)* | ||
| Yes | 16 | 50 |
| No | 16 | 50 |
*
Among eyes at treatment initiation, 22 (38.6%) were active, 34 (59.7%) were inactive, and 1 (1.8%) had unknown inflammatory status.
IMT, immunomodulatory therapy.